Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 5,156 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervical Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening

NCT02265120
View directory record Official record
Conditions
Cervical Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
20 Years to 70 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 25, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00551759
View directory record Official record
Conditions
Esophageal Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Cetuximab, Docetaxel, Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
109
States / cities
Lewes, Delaware • Newark, Delaware • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Not applicable Interventional

Adjuvant Oxytocin for Preinduction Ripening With a Foley catheter--a Clinical Trial

NCT00468520
View directory record Official record
Conditions
Pregnancy, Induced Labor, Cervical Ripening
Interventions
low dose oxytocin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 25, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

NCT04459715
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT), Placebo
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Phase 1Phase 2 Interventional

BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00057850
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 25, 2026, 4:35 PM EDT
Completed No phase listed Observational

Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer

NCT00824174
View directory record Official record
Conditions
Head and Neck Cancer, Skin Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial

NCT00790270
View directory record Official record
Conditions
Cervical Strain
Interventions
Cyclobenzaprine, Ibuprofen, Ibuprofen plus Cyclobenzaprine
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 25, 2026, 4:35 PM EDT
Active, not recruiting Phase 2 Interventional

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

NCT03565783
View directory record Official record
Conditions
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Cemiplimab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 4:35 PM EDT
Withdrawn Not applicable Interventional

A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.

NCT06422312
View directory record Official record
Conditions
Bladder Cancer, Bladder Stone, Bladder Outlet Obstruction, Renal Stone, Renal Disease
Interventions
Cystoscopy with RedPine flexible disposable cystoscope, Cystoscopy with standard of care flexible reusable scope
Device
Lead sponsor
Guangzhou Red Pine Medical Instrument Co., Ltd.
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Hersey, Pennsylvania • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

NCT01127581
View directory record Official record
Conditions
Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor
Interventions
MVI 200, Dinoprostone Vaginal Insert (DVI)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 25, 2026, 4:35 PM EDT
Withdrawn No phase listed Observational

Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device

NCT01133262
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 25, 2026, 4:35 PM EDT
Recruiting Not applicable Interventional

Physiologic MR Imaging of Salivary Gland Tumors

NCT04452162
View directory record Official record
Conditions
Salivary Gland Tumor
Interventions
MRI
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 25, 2026, 4:35 PM EDT
Completed No phase listed Observational

Optional Sub-study to Intraoperative Imaging With ICG Registry

NCT02651246
View directory record Official record
Conditions
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Interventions
data collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT

NCT01372527
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Cervical Cancer
Interventions
TopCare: Use of provider knowledge vs. automated system
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 75 Years
Enrollment
103,870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

NCT05816785
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
Cetuximab, Imatinib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 4:35 PM EDT
Terminated Phase 1 Interventional

Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck

NCT02201355
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck T1/2N0-2
Interventions
Intensity Modulated Radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Not applicable Interventional

Neck Drains for SLNDs

NCT03113526
View directory record Official record
Conditions
Neck Disease, Head and Neck Cancer
Interventions
remove drain
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 25, 2026, 4:35 PM EDT
Completed No phase listed Observational

Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma

NCT00165126
View directory record Official record
Conditions
Endometrial Carcinoma, Cervix Cancer, Carcinoma of the Uterus
Interventions
Radiation therapy
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 25, 2026, 4:35 PM EDT
Recruiting No phase listed Observational

Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules

NCT07226804
View directory record Official record
Conditions
Thyroid Nodules, Pulsed Field Ablation
Interventions
Questionnaire
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Phase 1 Interventional

PCA062 in pCAD-positive Tumors.

NCT02375958
View directory record Official record
Conditions
Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer
Interventions
PCA062
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Phase 1Phase 2 Interventional

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03109158
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
NC-6004, Cetuximab, 5-FU
Drug
Lead sponsor
NanoCarrier Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

NCT01256385
View directory record Official record
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Sutent + Taxol for Advanced Esophageal Cancer

NCT00730353
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Sunitinib malate, Paclitaxel
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Chicago, Illinois • Galesburg, Illinois • Bloomington, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 25, 2026, 4:35 PM EDT
Terminated Not applicable Interventional

Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria

NCT00785135
View directory record Official record
Conditions
Binocular Dysfunction, Vertical Heterophoria, Vision, Binocular, Vision Disparity
Interventions
Lenses containing prismatic correction, Lenses not containing prismatic correction
Device
Lead sponsor
Vision Specialists of Birmingham
Other
Eligibility
14 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Birmingham, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 25, 2026, 4:35 PM EDT